BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19137020)

  • 41. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
    Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
    Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
    Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
    Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Wnt/β-catenin signalling in adrenal physiology and tumour development.
    Berthon A; Martinez A; Bertherat J; Val P
    Mol Cell Endocrinol; 2012 Mar; 351(1):87-95. PubMed ID: 21930188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.
    Groen RW; Oud ME; Schilder-Tol EJ; Overdijk MB; ten Berge D; Nusse R; Spaargaren M; Pals ST
    Cancer Res; 2008 Sep; 68(17):6969-77. PubMed ID: 18757411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
    Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
    Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infrequent somatic mutations of the ICAT gene in various human cancers with frequent 1p-LOH and/or abnormal nuclear accumulation of beta-catenin.
    Imai M; Nakamura T; Akiyama T; Horii A
    Oncol Rep; 2004 Nov; 12(5):1099-103. PubMed ID: 15492799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular evidence of the independent origin of multiple Wilms tumors in a case of WAGR syndrome.
    Uccini S; Perotti D; Colarossi C; Stoppacciaro A; Sardella M; Mannarino O; Collini P; Casieri P; Cozzi D; Amoroso L; Spreafico F; Radice P; Dominici C
    Pediatr Blood Cancer; 2008 Sep; 51(3):344-8. PubMed ID: 18293378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway.
    Kim MS; Yoon SK; Bollig F; Kitagaki J; Hur W; Whye NJ; Wu YP; Rivera MN; Park JY; Kim HS; Malik K; Bell DW; Englert C; Perantoni AO; Lee SB
    J Biol Chem; 2010 May; 285(19):14585-93. PubMed ID: 20220130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
    Pritchard-Jones K; Fleming S
    Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
    Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
    Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis.
    Breuhahn K; Singh S; Schirmacher P; Bläker H
    J Pathol; 2008 Jul; 215(3):300-7. PubMed ID: 18491352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
    Udtha M; Lee SJ; Alam R; Coombes K; Huff V
    Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
    Ramani P; Cowell JK
    J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
    Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
    Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma.
    Castiglia D; Bernardini S; Alvino E; Pagani E; De Luca N; Falcinelli S; Pacchiarotti A; Bonmassar E; Zambruno G; D'Atri S
    Genes Chromosomes Cancer; 2008 Jul; 47(7):614-24. PubMed ID: 18384130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beta-catenin expression and mutation in adult and pediatric Wilms' tumors.
    Su MC; Huang WC; Lien HC
    APMIS; 2008 Sep; 116(9):771-8. PubMed ID: 19024596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
    Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants.
    Kim MK; Min DJ; Rabin M; Licht JD
    Oncogene; 2011 Feb; 30(7):832-42. PubMed ID: 20956941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutational analysis of WTX gene in Wnt/ beta-catenin pathway in gastric, colorectal, and hepatocellular carcinomas.
    Yoo NJ; Kim S; Lee SH
    Dig Dis Sci; 2009 May; 54(5):1011-4. PubMed ID: 18720004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.